This bill establishes a new Office of Alcohol and Drug Use Disorders Policy within New Jersey's Executive Branch, independent of the Department of the Treasury but reporting directly to the Governor. The office coordinates all state efforts related to substance use disorder treatment, prevention, and research across departments and counties. Key provisions include requiring an annual statewide Master Plan for services, reviewing county plans, distributing grants to localities, and creating a centralized treatment resource database. The office directly affects state agencies, counties, and treatment providers by centralizing coordination and funding recommendations for substance use disorder services.
New Jersey's S 3105 establishes a statewide tele-psychiatry program within the Department of Human Services (DHS) to provide remote mental health and substance abuse crisis care. The program allows licensed providers ("consulting providers") at one location ("consultant site") to deliver real-time video consultations to patients at hospitals or facilities ("referring sites") experiencing acute mental health crises. DHS must contract with a partner organization to implement the program statewide within three years, monitor its effectiveness through annual reports, and facilitate access for rural and critical access hospitals. The bill appropriates $4 million from the General Fund to cover implementation costs, including oversight, site monitoring, and payment rates for tele-psychiatry services. It directly affects hospitals seeking crisis care access, licensed mental health providers, and patients in acute need of psychiatric evaluation.
This bill authorizes licensed outpatient substance use disorder treatment programs in New Jersey to provide housing to patients receiving treatment, specifically for individuals needing both services. Programs must offer housing through a separate contract requiring patients to acknowledge repayment of housing subsidies, and must inform patients that housing and treatment are independent services not contingent on each other. The bill maintains existing criminal penalties for programs accepting payment for patient referrals while allowing treatment programs to own, lease, or manage housing units under state zoning and safety regulations.
This bill requires New Jersey hospitals to offer mental health evaluations to patients treated for drug overdoses before discharge. It mandates that all health insurance plans (including individual, group, hospital service, and medical service contracts) cover these evaluations at the same level as other medical treatments. The policy directly affects overdose patients receiving care at licensed acute care hospitals and insurers providing coverage in New Jersey. It applies to all relevant insurance contracts issued or renewed after the bill's effective date.
This bill increases state funding by $1.5 million for the Center for Great Expectations in Somerset, raising its FY2024 appropriation from $500,000 to $2.0 million. The Center provides safe housing and support services to over 1,000 individuals annually, including homeless or economically marginalized people, pregnant or parenting individuals, and those with mental health or substance use challenges. The additional funds will directly support three key programs: the state's only residential program for adolescents with mental health disorders, an adult residential program for pregnant women, and outpatient mental health/substance abuse services. The bill amends the state's annual budget to adjust the funding line for this specific program.
This bill (S 2144) updates licensing rules for residential substance use disorder treatment facilities in New Jersey. It requires applicants to submit independent financial audits (paid by the applicant) and undergo criminal background checks for all owners or major stakeholders (5%+ ownership), with licensure denied for financial misconduct or convictions involving fraud/dishonesty. The Department of Health must also conduct unannounced facility inspections. These changes directly affect facilities seeking or holding licenses and their owners, aiming to ensure financial accountability and safety through stricter vetting.
This Senate Resolution (SR 32) urges New Jersey's State Boards of Medical Examiners, Dentistry, Nursing, and Pharmacy to require ongoing training for healthcare professionals on opioid pain medication. The resolution specifically calls for continuing education covering responsible prescribing practices, non-opioid pain management alternatives, and recognizing signs of opioid misuse or addiction. It applies to all prescribers (like doctors, dentists, pharmacists) and relevant non-prescribers (such as nurses) who interact with patients on opioids. The resolution is non-binding and recommends these requirements remain in effect for two license renewal cycles, unless extended by the boards.
This New Jersey bill (S 349) updates licensing rules for residential substance use treatment facilities. It requires applicants to submit independent financial audits (paid by the applicant) and criminal background checks for owners/principals (denial if fraud/dishonesty convictions are found). Facilities must undergo annual unannounced inspections and file detailed annual reports on incidents like injuries, outbreaks, or staff misconduct. The bill also mandates transparency for funding applications, requiring disclosure of financials, ownership, and staff details to the Department of Health. These changes directly affect facilities seeking or maintaining licenses to operate in New Jersey.
S 2893 requires landlords to obtain written approval from New Jersey's Department of Health (DOH) before evicting or interfering with hospital operators or their successors. This applies to any "adverse possessory action," such as lease termination or removal from hospital property, directly affecting hospital operators, landlords, and the DOH. The bill mandates DOH approval for such actions based on "just cause," with violations resulting in civil penalties up to $1 million, license suspensions, and potential criminal charges for actions causing hospital closures. It also ensures hospitals can seek financial recovery for revenue losses due to unauthorized actions.
SJR 31 establishes the New Jersey Pharmacogenomics Commission to study how a person's genetic makeup affects medication effectiveness and safety (pharmacogenomics). The 13-member commission, appointed by the Governor and legislative leaders, will examine costs, benefits for patients and providers, applications like opioid crisis response, and potential reductions in adverse drug events. It must hold public hearings in northern and southern New Jersey within six months of forming and submit a final report to the Governor and Legislature within six months of its organization. The commission expires after submitting this report, which will inform potential future policy decisions. This is a study commission only - no new laws or funding are created by the bill.
